HomeCompareOSAPQ vs JNJ

OSAPQ vs JNJ: Dividend Comparison 2026

OSAPQ yields 14285.71% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OSAPQ wins by $1868328188208921344.00M in total portfolio value
10 years
OSAPQ
OSAPQ
● Live price
14285.71%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1868328188208921344.00M
Annual income
$1,842,950,648,126,759,800,000,000.00
Full OSAPQ calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — OSAPQ vs JNJ

📍 OSAPQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOSAPQJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OSAPQ + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OSAPQ pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OSAPQ
Annual income on $10K today (after 15% tax)
$1,214,285.71/yr
After 10yr DRIP, annual income (after tax)
$1,566,508,050,907,746,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, OSAPQ beats the other by $1,566,508,050,907,746,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OSAPQ + JNJ for your $10,000?

OSAPQ: 50%JNJ: 50%
100% JNJ50/50100% OSAPQ
Portfolio after 10yr
$934164094104460672.00M
Annual income
$921,475,324,063,379,900,000,000.00/yr
Blended yield
98.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

OSAPQ
No analyst data
Altman Z
-13.2
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OSAPQ buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOSAPQJNJ
Forward yield14285.71%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1868328188208921344.00M$30.3K
Annual income after 10y$1,842,950,648,126,759,800,000,000.00$4,689.40
Total dividends collected$1866648039868218112.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OSAPQ vs JNJ ($10,000, DRIP)

YearOSAPQ PortfolioOSAPQ Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$1,439,271$1,428,571.43$10,592$272.30+$1.43MOSAPQ
2$193,699,090$192,159,069.24$11,289$357.73+$193.69MOSAPQ
3$24,376,441,818$24,169,183,791.94$12,123$472.89+$24376.43MOSAPQ
4$2,868,716,750,186$2,842,633,957,441.24$13,141$629.86+$2868716.74MOSAPQ
5$315,716,708,842,374$312,647,181,919,674.60$14,408$846.81+$315716708.83MOSAPQ
6$32,495,195,455,130,188$32,157,378,576,668,850.00$16,021$1,151.60+$32495195455.11MOSAPQ
7$3,128,044,259,554,657,300$3,093,274,400,417,667,600.00$18,122$1,588.22+$3128044259554.64MOSAPQ
8$281,631,115,249,329,080,000$278,284,107,891,605,600,000.00$20,930$2,228.20+$281631115249329.06MOSAPQ
9$23,717,327,179,590,366,000,000$23,415,981,886,273,583,000,000.00$24,792$3,191.91+$23717327179590368.00MOSAPQ
10$1,868,328,188,208,921,400,000,000$1,842,950,648,126,759,800,000,000.00$30,274$4,689.40+$1868328188208921344.00MOSAPQ

OSAPQ vs JNJ: Complete Analysis 2026

OSAPQStock

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California. On May 7, 2024, ProSomnus, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full OSAPQ Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this OSAPQ vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OSAPQ vs SCHDOSAPQ vs JEPIOSAPQ vs OOSAPQ vs KOOSAPQ vs MAINOSAPQ vs ABBVOSAPQ vs MRKOSAPQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.